The MC Roundtable: how CDMO’s are responding to pharma’s top priorities in 2021 (part 1)
March 19, 2021
The drug manufacturing industry is increasingly enlisting outsourcing partners like CDMOs to address a broad range of megatrends which is making the current commercial realities of early stage drug development and manufacturing all the more complex.
In this roundtable with Manufacturing Chemist, Lynn Allen, MedPharm’s Vice President of Business Development, explores the most important aspects to consider in order to meet customer demands for both flexibility and operational excellence.
MedPharm is the world’s leading contract provider of topical and transdermal formulation development and manufacturing services. Our experts specialize in reducing risk and accelerating development times for generic and proprietary pharmaceutical customers through cost-effective and industry-leading performance testing models. Well-established as the global leader in dermal and transdermal product development, MedPharm also offers innovative solutions for airway, ophthalmic, otic, ungual, and other topical preparations. With locations in both the US and the UK, MedPharm is the CDMO of choice for developers around the globe.